A doctor (59) has been arrested by Delhi police’s Economic Offences Wing (EOW) for allegedly procuring two loans of Rs. 2.9 Crores and forging his wife’s signature and documents.
The complaint against the accused was filed by a woman who said that when she applied for a loan for her daughter’s higher studies, it was rejected by the bank saying that the latter had already availed a heavy loan and was a defaulter.
After finding out that her husband had taken two loans of Rs. 1,03,97,767 and Rs. 1,85,50,000 mentioning her as co-applicant, the woman filed a case in the Delhi High Court’s mediation centre in 2018 where a case of cheating and forgery was registered.
It was found that the accused had used forged KYC documents while filing the loan applications with NBFC.
India is reaching a landmark of 11 Crore inoculations as more than 10.8 crore doses have been administered as on April 13, 2021, till 8:00 PM.
Total Doses Administered: 10,85,33,085
In the last 24 hours: 40,04,521
People above 45 years of age:
1st Dose: 7,59,30,829
2nd Dose: 30,12,731
Cipla Ltd, an Indian Pharma giant has scaled up the production of Covid-19 medication Remdesivir, it announced on Tuesday.
In a statement to Reuters, the company said, “We have scaled up the production of Remdesivir by 2 times from the last wave of the pandemic. Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network.”
Cipla is working with authorities to restrict Remdesivir supply just to hospitals and places with a high burden of severe COVID-19 cases, it added.
NITI Aayog Member Dr VK Paul addressed a media briefing on Tuesday where he talked about the “rational, correct and judicial” use of Remdesivir and appealed to the physicians community to do the same.
He said Remdesivir is “only for those who require hospitalization and are on oxygen. That is the precondition.”
The use of the drug outside the established guideline is “unethical, irrational”, said Paul.
Those who are getting treated at home, are asymptomatic, or are showing mild symptoms, there’s no need for them to use this drug, said Paul.
There’s no question of using it in home setting, he said.
The Niti Aayog member also said that Remdesivir is a drug that “has to be supplied only to hospitals, not chemists” and urged the physician community of the country to ensure its rational use in the country.
“This(queuing) outside chemist shops to procure Remdesivir is creating distortions and panic. This is not going in the right way ,” said Paul.
The Central Government has fast-tracked emergency approval for foreign-produced jabs that have been granted similar clearances in other countries.
The decision came on Tuesday after NEGVAC recommended that COVID-19 vaccines which have been granted emergency approval for restricted use by authorities in the US, Europe, the UK, Japan or which are listed in the WHO Emergency Use Listing may be granted emergency use approval in India, mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial as per the provisions prescribed under Second Schedule of the New Drugs & Clinical Trials Rules 2019.
Accroding to a press release by the Union Ministry of Health, “The first 100 beneficiaries of such foreign vaccines shall be assessed for seven days for safety outcomes before it is rolled out for further immunization programme within the country. The Union Government, after due consideration, has accepted the recommendation of NEGVAC.”
Dr Harsh Vardhan, talking how human health could not be seen in isolation anymore, stressed on the need of ‘One Health’ approach, especially during COVID. He announced the creation of an Eco-Health initiative for India which will be supported by National Institute of One Health.
He elucidated that 64 per cent of all infectious diseases which have emerged between 1973 and 1994 had aetiology which was zoonotic in nature. While talking about zoonotic viruses, Harsh Vardhan said India is one of the four global hotspots for the emergence of zoonotic diseases and added that “we are struggling even after 15 months”.
A notice has been released by the Drugs Controller General of India ordering all the States and UTs to perform special surveillance and inquiry to avoid hoarding, black marketing and overcharging for Remdesivir.
In addition to this, the DCGI wrote to all the states and UTs that, “You are requested to instruct your enforcement staff immediately to keep strict and vigil, especially at sensitive places and to take stringent action against hoarding/black marketing/overcharging for Remdesivir, by conducting a special drive of monitoring and investigation, so that any such incidence for the drug is prevented.”
New Delhi- Russian -made first COVID-19 vaccine in the world gets final approval in India , it will be manufactured by five pharma firms in the country and 850 million doses are going to be produced annually. It is expected to supply limited doses by the end of April.
The India’s drug regulator , DCGI has approved the Russina vaccine fater it got a green signal from the Subject expert committee that comes under CDSCO
“M/s DRL was permitted to conduct a Phase-II/III clinical trial in the country. The firm has submitted interim data from the ongoing Phase-II/III clinical trial in the country. The data from the clinical trial is being continuously assessed by the CDSCO in consultation with the Subject Expert Committee (SEC) as a rapid regulatory response. The SEC consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine, etc.” says statement issued by the union health ministry
The vaccine will be administered on above 18 years of age group with a interval of 21 days, “The vaccine is indicated for active immunization to prevent COVID-19 disease in individuals of ≥ 18 years of age. The vaccine should be administered intramuscularly in two doses of 0.5 ml each with interval of 21 days. (Day 0: Component I & Day 21: Component II). The vaccine has to be stored at -18°C. The vaccine comprises of two components I & II, which are not interchangeable. After careful consideration, the recommendations of the SEC have been accepted by the Drugs Control General (India). M/s DRL will import the vaccine for use in the country.” says the statement.
Dr Reddy’s Laboratories co-chairman and managing director GV Prasad said, “We are very pleased to obtain the emergency use authorisation for Sputnik V in India. With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. This will enable us to contribute to our nation’s effort of vaccinating a significant proportion of our population.”